简介:GB/T29847-2013《印制板用铜箔试验方法》国家标准于2013年11月出版。该标准由咸阳瑞德科技有限公司、苏州福田金属有限公司、广东生益科技股份有限公司、山东金宝电子股份有限公司、联合铜箔(惠州)有限公司负责起草的标准对印制板用铜箔外观、尺寸、物理性能、工艺性能、特殊性能检验涉及二十项检验方法(即铜箔表面检查、针孔检查、处理和未处理铜箔的总厚度和轮廓因数检验、单位面积质量检验、可分离载体铜箔的单位面积质量检验、可蚀刻载体铜箔的单位面积质量检验、表面粗糙度和轮廓检验、拉伸强度和延伸率检验、弯曲疲劳和延展性检验、剥离强度检验、薄铜箔与载体的分离强度检验、过硫酸铵蚀刻法、氯化铁蚀刻法”氯化铜蚀刻法、化学清洗性检验、可焊性检验、处理转移(处理完善性)检验、铜箔或镀铜层的纯度检验、质量电阻率检验及显微剖切试样制作方法)的试样要求及检验程序作出了具体规定。
简介:Objective:ResponseEvaluationCriteriainSolidTumors(RECIST)guidelineversion1.0(RECIST1.0)wasproposedasanewguidelineforevaluatingtumorresponseandhasbeenwidelyacceptedasastandardizedmeasure.WithanumberofissuesbeingraisedonRECIST1.0,however,arevisedRECISTguidelineversion1.1(RECIST1.1)wasproposedbytheRECISTWorkingGroupin2009.ThisstudywasconductedtocompareCTtumorresponsebasedonRECIST1.1vs.RECIST1.0inpatientswithadvancedgastriccancer(AGC).Methods:Wereviewed61AGCpatientswithmeasurablediseasesbyRECIST1.0whowereenrolledinotherclinicaltrialsbetween2008and2010.Thesepatientswereretrospectivelyre-analyzedtodeterminetheconcordancebetweenthetworesponsecriteriausingtheκstatistic.Results:ThenumberandsumoftumordiametersofthetargetlesionsbyRECIST1.1weresignificantlylowerthanthosebyRECIST1.0(P<0.0001).However,therewasexcellentagreementintumorresponsebetweenRECIST1.1andRECIST1.0(κ=0.844).Theoverallresponserates(ORRs)accordingtoRECIST1.0andRECIST1.1were32.7%(20/61)and34.5%(20/58),respectively.Onepatientwithpartialresponse(PR)basedonRECIST1.0wasreclassifiedasstabledisease(SD)byRECIST1.1.OftwopatientswithSDbyRECIST1.0,onewasdowngradedtoprogressivediseaseandtheotherwasupgradedtoPRbyRECIST1.1.Conclusions:RECIST1.1providedalmostperfectagreementwithRECIST1.0intheCTassessmentoftumorresponseofAGC.
简介:全血及成分血质量要求(GB18469-2012)(以下简称国标)由卫生部联合国家标准化管理委员会于2012年5月11日发布,7月1日实施。2012年2月卫生部颁布血站技术操作规程(2012版)(以下简称规程),对献血者健康检查、全血采集、血液成分制备、
简介:MicroRNAs(miRNAs)aresmall,non-codingsingle-strandedRNAsthatcanmodulatetargetgeneexpressionatposttranscriptionallevelandparticipateincellproliferation,differentiation,andapoptosis.Tcellshaveimportantfunctionsinacquiredimmuneresponse;miRNAsregulatethisimmuneresponsebytargetingthemRNAsofgenesinvolvedinTcelldevelopment,proliferation,differentiation,andfunction.Forinstance,miR-181familymembersfunctioninprogressionbytargetingBcl2andCD69,amongothers.MiR-17tomiR-92clustersfunctionbybindingtoCREB1,PTEN,andBim.ConsideringthatthesuppressionofTcell-mediatedimmuneresponsesagainsttumorcellsisinvolvedincancerprogression,weshouldinvestigatethemechanismbywhichmiRNAregulatesTcellstodevelopnewapproachesforcancertreatment.